More than half of the job losses stem from the closure of the genome sequencer’s San Diego office amid an ongoing industry slump.
Pacific Biosciences to lay off 195 employees as part of cost cuts Read More »
FDA inspectors found Cue made unauthorized changes to its COVID-19 kits that “reduced the reliability of the tests.”
FDA advises against using Cue Health COVID-19 tests, sends warning letter Read More »
Despite an “unusual” rise in inpatient volumes, executives at most of the leading for-profit health systems said they remain focused on outpatient investments.
Inpatient admissions lift for-profit providers’ revenue during Q1 Read More »
At that time, current chief operating officer Jim Rechtin will take the reins of the health insurer, which is struggling with challenges in Medicare Advantage.
The rate increases will apply to equipment including syringes, face masks and surgical gloves.
The rate hikes focus on areas where the Biden administration has sought to boost domestic production, such as medical supplies that were essential to the COVID-19 pandemic response.
CASI Pharmaceuticals, Inc. today reported financial results for the three months ended March 31, 2024.
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS Read More »
Genprex, Inc. today announced that the first patient has been enrolled and dosed in the Company’s Phase 1 dose escalation portion of the Acclaim-3 clinical study of Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy in combination with Genentech’s Tecentriq® to treat patients with extensive-stage small cell lung cancer (ES-SCLC).
Neurocrine Biosciences, Inc. presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH).
Allurion Technologies, Inc. today announced its financial results for the first quarter ended March 31, 2024, and provided a business update.
Allurion Reports First Quarter 2024 Financial Results and Provides Business Update Read More »
